JP2013544492A - 新規な抗原結合タンパク質 - Google Patents

新規な抗原結合タンパク質 Download PDF

Info

Publication number
JP2013544492A
JP2013544492A JP2013527341A JP2013527341A JP2013544492A JP 2013544492 A JP2013544492 A JP 2013544492A JP 2013527341 A JP2013527341 A JP 2013527341A JP 2013527341 A JP2013527341 A JP 2013527341A JP 2013544492 A JP2013544492 A JP 2013544492A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
binding protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013527341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544492A5 (https=
Inventor
ニール、ジェームズ、クラーク
キョン、オー、ジョハンソン
ズデンカ、ルドミラ、ジョナク
アレクサンダー、エイチ．テイラー
クリストファー、ビー．ホプソン
スティーブン、エイチ．トゥルーリ
ズデンカ、ハスコバ
ジュディサン、エム．リー
ジョン、アール．ホワイト
ユ、シュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013544492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2013544492A publication Critical patent/JP2013544492A/ja
Publication of JP2013544492A5 publication Critical patent/JP2013544492A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013527341A 2010-09-03 2011-09-02 新規な抗原結合タンパク質 Pending JP2013544492A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37984010P 2010-09-03 2010-09-03
US61/379,840 2010-09-03
US201161440460P 2011-02-08 2011-02-08
US61/440,460 2011-02-08
PCT/US2011/050322 WO2012031198A2 (en) 2010-09-03 2011-09-02 Novel antigen binding proteins

Publications (2)

Publication Number Publication Date
JP2013544492A true JP2013544492A (ja) 2013-12-19
JP2013544492A5 JP2013544492A5 (https=) 2014-10-23

Family

ID=45773540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527341A Pending JP2013544492A (ja) 2010-09-03 2011-09-02 新規な抗原結合タンパク質

Country Status (21)

Country Link
US (1) US9085622B2 (https=)
EP (1) EP2611829A4 (https=)
JP (1) JP2013544492A (https=)
KR (1) KR20130101047A (https=)
CN (1) CN103189391A (https=)
AU (1) AU2011295726B2 (https=)
BR (1) BR112013005242A2 (https=)
CA (1) CA2809443A1 (https=)
CL (1) CL2013000566A1 (https=)
CO (1) CO6690769A2 (https=)
CR (1) CR20130128A (https=)
EA (1) EA201390328A1 (https=)
MA (1) MA34555B1 (https=)
MX (1) MX2013002535A (https=)
NZ (1) NZ607680A (https=)
PE (1) PE20140133A1 (https=)
PH (1) PH12013500353A1 (https=)
SG (2) SG10201401681PA (https=)
TW (1) TW201302793A (https=)
UY (1) UY33591A (https=)
WO (1) WO2012031198A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538827A (ja) * 2013-10-04 2016-12-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３に特異的に結合する抗体
JP2022118731A (ja) * 2018-03-29 2022-08-15 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
DK2797957T3 (da) 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
EP3590538A1 (en) * 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
CN104093742A (zh) * 2011-12-05 2014-10-08 诺华股份有限公司 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体
EP2807272A1 (en) * 2012-01-27 2014-12-03 Ventana Medical Systems, Inc. Devices and methods for detecting bio-analytes using optically decipherable patterns
AR093778A1 (es) 2012-11-08 2015-06-24 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4
MA38165A1 (fr) 2012-11-08 2018-07-31 Hoffmann La Roche Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
MX2016014416A (es) 2014-05-14 2017-02-23 Hoffmann La Roche Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
MX379365B (es) 2014-06-30 2025-03-11 Tarveda Therapeutics Inc Conjugados y partículas direccionados y formulaciones de estos.
CA2954791C (en) * 2014-07-14 2025-11-18 The Regents Of The University Of California CRISPR/CAS TRANSCRIPTIONAL MODULATION
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof
TWI727380B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
AU2017235450A1 (en) 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
PL3468621T3 (pl) * 2016-06-10 2023-01-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Domena rdzeniowa aneksyn i jej zastosowania w dostarczaniu antygenu i szczepieniu
CN106543286A (zh) * 2016-12-07 2017-03-29 上海邦耀生物科技有限公司 一种去岩藻糖抗her2抗体及其应用
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
US11530273B2 (en) * 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
WO2019173417A1 (en) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-tip-1 antibodies and uses thereof
JP7842011B2 (ja) * 2019-09-27 2026-04-07 アジェナス インコーポレイテッド ヘテロ二量体タンパク質
US20250243261A1 (en) * 2022-04-08 2025-07-31 Cz Biohub Sf, Llc Antibody compositions and optimization methods
CN116286828B (zh) * 2023-05-12 2023-08-18 中国人民解放军军事科学院军事医学研究院 一种寡聚核酸siRNA及其在制备用于预防和治疗肝癌的药物中的应用
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
CN120352624B (zh) * 2025-06-25 2025-08-26 北京溯本源和生物科技有限公司 一种用于hpv18型e7蛋白检测的单克隆抗体组合及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521913A (ja) * 2005-12-30 2009-06-11 ウー３・ファルマ・アクチェンゲゼルシャフト Ｈｅｒ−３に対して誘導された抗体及びその使用

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6639061B1 (en) 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
AU4155696A (en) 1994-11-09 1996-06-06 Regents Of The University Of California, The Immunoliposomes that optimize internalization into target cells
CA2589421C (en) 1996-03-27 2012-12-18 Genentech, Inc. Erbb3 antibodies
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
DE69736806T3 (de) 1996-03-27 2015-10-08 Genentech, Inc. ErbB3 ANTIKÖRPER
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA2258721C (en) 1996-07-12 2014-09-09 Genentech, Inc. Chimeric heteromultimer adhesins
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6723694B1 (en) 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6416168B1 (en) 1997-07-15 2002-07-09 Silverbrook Research Pty Ltd Pump action refill ink jet printing mechanism
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
DK1510579T3 (da) 1998-02-04 2009-11-30 Genentech Inc Anvendelse af heregulin som en epitelcellevækstfaktor
AU2003203831B2 (en) 1998-02-04 2006-08-10 Genentech, Inc. Use of heregulin as an epithelial cell growth factor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
AU2004200705A1 (en) 1998-05-15 2004-03-18 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
NZ511019A (en) 1998-11-07 2003-11-28 Genentech Inc An isolated ligand, which is a heregulin polypeptide, to activate HER2 and/or HER3 receptors to induce inner ear hair cell generation
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1169352A4 (en) * 1999-04-14 2005-05-04 Smithkline Beecham Corp ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6710186B2 (en) 1999-06-14 2004-03-23 Wisconsin Alumni Research Foundation Oligomers and polymers of di-substituted cyclic imino carboxylic acids
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
US7732157B1 (en) 1999-09-30 2010-06-08 Tumor Biology Investment Group Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
ATE271691T1 (de) 2000-01-12 2004-08-15 Ventana Med Syst Inc Verfahren zum nachweis der effektivität einer krebstherapie
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU2007216733A1 (en) 2000-04-11 2007-09-27 Genentech, Inc. Multivalent antibodies and uses therefor
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6277640B1 (en) 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
ATE356575T1 (de) 2000-11-24 2007-04-15 Freudenberg Carl Kg Bodenwischer
AU2008200400B2 (en) 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
NZ527977A (en) 2001-02-12 2005-10-28 Medarex Inc Human monoclonal antibodies to FC alpha receptor (CD89)
WO2002081649A2 (en) 2001-04-06 2002-10-17 The Trustees Of The University Of Pennsylvania ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
CA2445053A1 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US7745398B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003001602A2 (en) 2001-06-21 2003-01-03 Akzo Nobel N.V. Manufacturing a solar cell foil connected in series via a temporary substrate
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
DE10137374A1 (de) 2001-07-31 2003-02-27 Ipk Inst Fuer Pflanzengenetik Verfahren zur Herstellung von Arachidonsäure in transgenen Organismen
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2008200654B2 (en) 2001-08-09 2010-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Inhibitors of HER3 activity
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003218600C1 (en) 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
JP4132912B2 (ja) 2002-03-26 2008-08-13 日東電工株式会社 ゲル電解質とその製造方法とその利用
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
AU2003251597A1 (en) 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
GB0225282D0 (en) 2002-10-31 2002-12-11 Astrazeneca Ab assay
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
KR20060017585A (ko) 2003-04-04 2006-02-24 유니베르시떼 드 로잔느 암 치료용 펩타바디
WO2004094463A2 (en) 2003-04-18 2004-11-04 University Of Florida Research Foundation, Inc. Peptide inhibitors of autophosphorylation protein kinases
CA2527680A1 (en) 2003-05-30 2005-06-02 Astrazeneca Uk Limited Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
JP2007515946A (ja) 2003-06-13 2007-06-21 オンコマックス アクイジション コーポレイション 抗腫瘍二元機能融合タンパク質の調製および適用
US20050232931A1 (en) 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US20040254108A1 (en) 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins
US6836094B1 (en) 2003-07-01 2004-12-28 International Truck Intellectual Property Company, Llc Motor vehicle battery disconnect switch circuits
WO2005040339A2 (en) 2003-07-18 2005-05-06 The Regents Of The University Of California Aptamers to human epidermal growth factor receptor-3
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
WO2005013804A2 (en) 2003-08-05 2005-02-17 Euro-Celtique S.A. ErbB RECEPTOR METHODS AND KITS FOR MONITORING CHEMOTHERAPY RESISTANCE
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1673399B1 (en) 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US7402399B2 (en) 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
CA2543830A1 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
JP2007510708A (ja) 2003-11-06 2007-04-26 ファイザー・プロダクツ・インク 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
US7754441B2 (en) 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1696963A2 (en) 2003-12-24 2006-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005079434A2 (en) 2004-02-17 2005-09-01 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
EP1718323B1 (en) 2004-02-20 2011-12-07 The Trustees of The University of Pennsylvania Binding peptidomimetics and uses of the same
EP1796711A2 (en) 2004-04-22 2007-06-20 Oregon Health and Science University Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20070197430A1 (en) 2004-06-24 2007-08-23 Jonathan Baell Conjugates And Therapeutic Uses Thereof
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2583230A1 (en) 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006058120A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
PT1828249E (pt) * 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
WO2006063042A2 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
WO2006068640A1 (en) 2004-12-21 2006-06-29 Cell Signaling Technology, Inc. Protein phosphorylation in egfr-signaling pathways
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
CA2593697A1 (en) 2005-01-11 2006-07-20 Molecular Logix, Inc. Pan-her antagonists and methods of use
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
WO2006084018A2 (en) 2005-02-02 2006-08-10 Monogram Biosciences, Inc. Methods for determining responsiveness to cancer therapy
PL1871805T3 (pl) 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
US7718626B2 (en) 2005-02-17 2010-05-18 University Of Maryland, Baltimore ErbB3 binding protein compositions and methods of use
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
CA2599606A1 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
JP2008535795A (ja) 2005-03-07 2008-09-04 ターゲッティド・モレキュラー・ダイアグナスティクス・エルエルシー チロシンキナーゼインヒビター組成物、並びに疾患の治療におけるそれらの製造及び使用のための方法
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
CA2604032C (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
WO2007015935A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
CA2624086A1 (en) 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
WO2007050495A2 (en) 2005-10-26 2007-05-03 Children's Medical Center Corporation Method to prognose response to anti-egfr therapeutics
EP1792622A1 (en) 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
EP1963368B3 (en) * 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
EP1800695A1 (en) 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA-constructs
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
WO2007089871A2 (en) 2006-02-01 2007-08-09 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP2049568A2 (en) 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
WO2007145862A2 (en) 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
CN101627053A (zh) * 2006-06-12 2010-01-13 西福根有限公司 泛细胞表面受体特异的治疗剂
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
US20100316626A1 (en) 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
US8936780B2 (en) 2006-08-30 2015-01-20 Advanced Cardiovascular Systems, Inc. Stimuli responsive polyester amide particles
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
JP4958975B2 (ja) 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
NZ575827A (en) 2006-09-21 2012-02-24 Prometheus Lab Inc Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
US20080076139A1 (en) 2006-09-21 2008-03-27 Sharat Singh Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
US20080112961A1 (en) 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
CA2668831A1 (en) 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
WO2008140493A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
EP2097754B2 (en) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
SG177225A1 (en) 2006-12-01 2012-01-30 Agency Science Tech & Res Cancer-related protein kinases
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
AU2007343610C1 (en) 2007-01-17 2013-11-07 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
PE20090190A1 (es) 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
WO2008119493A1 (en) 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
FR2915115B1 (fr) 2007-04-23 2010-09-10 Sames Technologies Organe de pulverisation,dispositif de projection comportant un tel organe,installation de projection et methode de nettoyage d'un tel organe
CA2688477C (en) 2007-06-01 2020-12-22 The Regents Of The University Of California Multigene prognostic assay for lung cancer
BRPI0812777A2 (pt) 2007-06-06 2014-12-02 Hoffmann La Roche Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir
WO2009045579A2 (en) 2007-06-14 2009-04-09 The Regents Of The University Of California Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
US8501417B2 (en) 2007-06-26 2013-08-06 Vanderbilt University Immunological compositions as cancer biomarkers and/or therapeutics
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2179291B1 (en) 2007-07-13 2014-10-22 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
WO2009023266A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
EP2205277B1 (en) 2007-10-22 2017-07-26 Genmab A/S Novel antibody therapies
JP5620106B2 (ja) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
CA2716670A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
WO2009134870A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CA2727278A1 (en) 2008-06-16 2010-01-21 Immunogen, Inc. Novel synergistic effects
EP2138511A1 (en) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
EP2316026A1 (en) 2008-07-25 2011-05-04 Merck Patent GmbH Method of determination of receptor binding saturation effected by monoclonal antibodies
US8056451B2 (en) 2008-07-28 2011-11-15 Irwin Industrial Tool Company Locking pliers
US20100033482A1 (en) 2008-08-11 2010-02-11 Interactive Relighting of Dynamic Refractive Objects Interactive Relighting of Dynamic Refractive Objects
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
KR20110084196A (ko) 2008-09-26 2011-07-21 유레카 쎄라퓨틱스, 인코포레이티드 다양한 글리코실화 패턴을 가진 세포계 및 단백질
WO2010051502A2 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
US8900549B2 (en) 2008-10-31 2014-12-02 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US20100169729A1 (en) 2008-12-30 2010-07-01 Datta Shamanna M Enabling an integrated memory controller to transparently work with defective memory devices
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
JP2012515353A (ja) 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
JP5384672B2 (ja) 2009-02-24 2014-01-08 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｓ−ＥｒｂＢ−３の使用
WO2010099186A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Her2 antibody compositions
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
EP2425009A4 (en) 2009-04-29 2013-01-23 Trellis Bioscience Llc Improved antibodies immunoreactive with heregulin-coupled her3
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
EP3309168A1 (en) 2009-08-06 2018-04-18 F. Hoffmann-La Roche AG Method to improve virus removal in protein purification
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
EA201200195A1 (ru) 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
WO2011031840A1 (en) 2009-09-09 2011-03-17 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
JP5898082B2 (ja) 2009-10-07 2016-04-06 マクロジェニクス，インコーポレーテッド フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
AU2010303443A1 (en) 2009-10-09 2012-04-19 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-Her 3 antibodies
AU2010306774A1 (en) 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
EP2896632B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
EP2542699A4 (en) 2010-03-03 2013-10-02 Targeted Molecular Diagnostics Llc METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
MX343227B (es) 2010-04-09 2016-10-28 Aveo Pharmaceuticals Inc Anticuerpos anti-erbb3.
WO2011139629A2 (en) 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
US20130108547A1 (en) 2010-05-13 2013-05-02 Fox Chase Cancer Center Recombinantly Produced Antibodies Targeting ErbB Signaling Molecules and Methods of Use Thereof for the Diagnosis and Treatment of Disease
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
WO2012103341A1 (en) 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
WO2012106578A1 (en) 2011-02-04 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
RU2018108836A (ru) 2011-02-04 2019-03-14 Дженентек, Инк. ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
CA2829110C (en) 2011-03-06 2019-01-15 Merck Serono S.A. Low fucose cell lines and uses thereof
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521913A (ja) * 2005-12-30 2009-06-11 ウー３・ファルマ・アクチェンゲゼルシャフト Ｈｅｒ−３に対して誘導された抗体及びその使用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538827A (ja) * 2013-10-04 2016-12-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３に特異的に結合する抗体
US10179815B2 (en) 2013-10-04 2019-01-15 Ventana Medical Systems, Inc. Antibodies specifically binding to HER3
JP2022118731A (ja) * 2018-03-29 2022-08-15 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子
JP7545437B2 (ja) 2018-03-29 2024-09-04 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子
JP2024164153A (ja) * 2018-03-29 2024-11-26 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子
JP7825000B2 (ja) 2018-03-29 2026-03-05 ハミングバード・バイオサイエンス・プライベート・リミテッド Ｈｅｒ３抗原結合性分子

Also Published As

Publication number Publication date
BR112013005242A2 (pt) 2016-06-28
MX2013002535A (es) 2013-06-03
AU2011295726A1 (en) 2013-03-21
CR20130128A (es) 2013-06-28
CL2013000566A1 (es) 2014-01-24
CO6690769A2 (es) 2013-06-17
CN103189391A (zh) 2013-07-03
EP2611829A4 (en) 2014-05-07
UY33591A (es) 2012-03-30
AU2011295726B2 (en) 2014-11-06
PE20140133A1 (es) 2014-02-09
KR20130101047A (ko) 2013-09-12
PH12013500353A1 (en) 2013-03-25
NZ607680A (en) 2015-02-27
SG187930A1 (en) 2013-03-28
EA201390328A1 (ru) 2013-08-30
EP2611829A2 (en) 2013-07-10
CA2809443A1 (en) 2012-03-08
US9085622B2 (en) 2015-07-21
TW201302793A (zh) 2013-01-16
US20130156779A1 (en) 2013-06-20
MA34555B1 (fr) 2013-09-02
WO2012031198A3 (en) 2012-05-18
SG10201401681PA (en) 2014-07-30
WO2012031198A2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
US9085622B2 (en) Antigen binding proteins
JP7062704B2 (ja) アゴニスト性ｉｃｏｓ結合タンパク質
WO2016059602A2 (en) Methods of treating cancer and related compositions
CN113166245B (zh) SIRPα结合蛋白及其使用方法
CN109475602B (zh) 抗pd-l1和il-2细胞因子
KR101721678B1 (ko) 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
US20230295313A1 (en) Il1rap binding proteins
AU2017204686B2 (en) Compositions and methods for detecting and treating esophageal cancer
TWI873112B (zh) 與TfR結合之雙專一性抗體
CN113195539A (zh) 药物组合
JP2022529232A (ja) 抗ｈｅｒ２結合分子
CN116940597A (zh) 多特异性抗体及其用途
KR20220103961A (ko) 약제학적 조합물 및 이의 용도
TW202216788A (zh) 與GPC3及TfR結合之雙特異性抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160902

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170404